GI Protocols

Colorectal Cancer

1. CALGB 80702:  A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
   PI: William Sikov, MD
   Sites: Rhode Island Hospital, The Miriam Hospital

2. BRUOG 254: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study
   PI: Howard Safran, MD
   Sites: Rhode Island Hospital, The Miriam Hospital

3. ACCRU MORAb: A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects with Chemorefractory Metastatic Colorectal Cancer
   PI: Howard Safran, MD
   Sites: Rhode Island Hospital, The Miriam Hospital

4. BrUOG CR-261: Single Agent Adjuvant Aflibercept (ziv-Aflibercept) for Patients with Resected or Ablated Metastatic Colorectal Cancer: A Randomized Phase II Study
   PI: Howard Safran, MD
   Sites: Rhode Island Hospital, The Miriam Hospital

Esophageal Cancer

1. RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
   PI: Howard Safran, MD
   Sites: Rhode Island Hospital, The Miriam Hospital

2. CALGB 80803: Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
   PI: Kimberly Perez, MD
   Sites: Rhode Island Hospital, The Miriam Hospital

Pancreas Cancer

1. RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
   PI: Howard Safran, MD
   Sites: Rhode Island Hospital, The Miriam Hospital

2. BrUOG P-278 - FOLFOX-A For Pancreatic Cancer: A Brown University Oncology Research Group Study
   PI: Howard Safran, MD
   Sites: Rhode Island Hospital, The Miriam Hospital

Liver Cancer

1. LS-P-BRISK TA: A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma: The BRISK TA Study
   PI: Howard Safran, MD
   Sites: Rhode Island Hospital, The Miriam Hospital